Randomized Clinical Trial of the Effectiveness of a Home-Based Advanced Practice Psychiatric Nurse Intervention: Outcomes for Individuals with Serious Mental Illness and HIV by Hanrahan, Nancy P. et al.
Hindawi Publishing Corporation
Nursing Research and Practice
Volume 2011, Article ID 840248, 10 pages
doi:10.1155/2011/840248
Research Article
Randomized ClinicalTrial oftheEffectiveness ofa Home-Based
Advanced Practice PsychiatricNurse Intervention:Outcomesfor
IndividualswithSerious MentalIllness andHIV
Nancy P.Hanrahan,1,2,3 Evan Wu,1 Deena Kelly,1 Linda H.Aiken,1,2 and Michael B. Blank2,4
1Center for Health Outcomes and Policy Research, School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia,
PA 19204-4217, USA
2Leonard Davis Institute of Health Economics, University of Pennsylvania, 3641 Locust Walk, Philadelphia, PA 19104-6218, USA
3Robert Wood Johnson Foundation Nurse Faculty Scholars Program, RWJF, P.O. Box 2316, Route 2 and College Road East,
Princeton, NJ 08543, USA
4Center for Mental Health Policy, School of Medicine, Department of Psychiatry, University of Pennsylvania,
3535 Market Street 3rd Floor, Philadelphia, PA 19104-2648, USA
Correspondence should be addressed to Nancy P. Hanrahan, nancyp@nursing.upenn.edu
Received 16 December 2010; Accepted 9 March 2011
Academic Editor: Terry Fulmer
Copyright © 2011 Nancy P. Hanrahan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Individuals with serious mental illness have greater risk for contracting HIV, multiple morbidities, and die 25 years younger than
thegeneral population. Thishigh need andhighcost subgroup face uniquebarriers to accessing required health carein the current
healthcare system.The eﬀectiveness of anadvanced practice nurse model of care managementwas assessedin a four-year random
controlled trial. Results are reported in this paper. In a four-year random controlled trial, a total of 238 community-dwelling
individuals with HIV and serious mental illness (SMI) were randomly assigned to an intervention group (n = 128) or to a control
group (n = 110). Over 12 months, the intervention group received care management from advanced practice psychiatric nurse,
and the control group received usual care. The intervention group showed signiﬁcant improvement in depression (P = .012) and
the physical component of health-related quality of life (P = .03) from baseline to 12 months. The advanced practice psychiatric
nurse intervention is a model of care that holds promise for a higher quality of care and outcomes for this vulnerable population.
1.Introduction
Peoplewith seriousmental illness (SMI),such asschizophre-
nia or bipolar disorder, are at increased risk of contracting
HIV [1]. Contributing factors include poverty, residing in
disadvantaged neighborhoods, high substance use, cognitive
impairment,andpooraccesstohealthcare[2,3].Individuals
with SMI and HIV have complex care needs. Common
treatment regimens for SMI and HIV include large numbers
of medications with troublesome side eﬀects and frequent
appointmentswith multipleproviders. Navigating thehealth
care system, in which general medical care and mental
health care treatment operate in silos, requires a high level
of communication and organizational skills, skills that are
often compromised in this population [4]. The challenge is
to provide resources that connect this population to high-
quality care and appropriate services that maintain health
and functioning in the face of disease progression and ensure
that this care is coordinated across multiple providers.
Research shows that care management models with
advanced practice registered nurses (APRNs) as providers
improveoutcomesforhigh-riskpopulations[5–7].However,
the eﬀectiveness of these models has not been studied
in the population with SMI and comorbid HIV. In this
paper, we report results from a randomized controlled trial
that tested a care management intervention delivered by
advanced practice psychiatric nurses to improve outcomes
for individuals with SMI and HIV.2 Nursing Research and Practice
2.Background
Serious mental illness (SMI) indicates signiﬁcant cognitive,
mood, or behavioral symptoms that interfere with an indi-
vidual’s capacity to socialize, plan, organize, and function
[8].Diagnoses most associated with SMIincludeschizophre-
nia, bipolar disorders, and major depression. Individuals
with SMI have higher prevalence of HIV infection than
individuals in the general population [1]. Seroprevalence
of HIV infection in the U.S. population is 0.43% [9]. One
study of Medicaid beneﬁciaries with SMI reported the risk of
HIV infection at 3.7%, with HIV prevalence among people
withschizophrenia at2.8%andprevalenceamongthosewith
aﬀective disorders at 4.6% [1]. Cooccurrence of SMI and a
substance use disorder triples the risk of HIV infection [1].
Recent evidence of poor general health of individuals
with SMI adds to the complexity of their health conditions.
Research shows that persons with SMI die 25 years earlier
than those in the general population[10]. One study showed
their average age of death to be 51 years, compared with
76 years for Americans overall [11]. Compared with the
general population, persons with SMI are 3.4 times more
likely to die from heart disease or diabetes, 3.8 times more
likely to die from accidents, 5.0 times more likely to die
from respiratory ailments, and 6.6 times more likely to die
from pneumonia inﬂuenza [12, 13]. These disparities are
hypothesized to be related to high rates of undetected and
untreated general medical conditions. Additionally a high
prevalence of metabolic syndromes and infectious diseases
have been associated with persons with SMI [14, 15]. Due
to system barriers, this population does not regularly access
primary care providers and receive routine screening and
treatment for these conditions.
Fragmented mental health care and physical health care
systems exact their toll on this population and use scarce
public resources ineﬀectively, and ineﬃciently. Systems for
thedeliveryofmentalhealth,substanceabusetreatment, and
general medical care operate independently, communicate
with one another ineﬃciently and often have diﬀerent
ﬁnancing arrangements and policies [16]. Research shows
that SMI consumers have legitimate concerns that their
generalmedicalneedsma ybedismissedassymptomsoftheir
mental illness [17]. Their physical problems are often missed
by medical providers and go untreated [17, 18]. Studies
describe long wait times, unsupportive health care staﬀ,
disrespectful communication, and even ridicule [19]. Such
encountersaddtothestigmatizationandemotionalsuﬀering
of this population. Avoiding care or being dismissed when
seekingcareexacerbateshealthproblemsandultimatelyadds
to costs of health care [12].
The public health stakes are high and the problems have
complex physical and psychological dimensions. Innovative
solutions are needed that bridge organization and profes-
sional silos, improve communication of essential clinical
information, and provide care management and social sup-
ports to prevent costly relapse and other adverse outcomes
in this vulnerable population [18]. One such innovation is to
link these individuals to a professional with the knowledge
and skills to assess, treat, and manage general medical
and mental health problems while ensuring they remain
connected with their usual care providers, such as case man-
agers, physicians, and health care systems. APRNs have such
specialty education and provide highly skilled care that
focuses ongeneral medical, mental health, and substance use
issues. Many high-risk populations, such as low-birth weight
babies, patients with congestive heart failure, and elders with
cognitive impairment, have responded with better outcomes
when they received APRN models of care [5, 20, 21].
Despite evidence of risk factors associated with SMI and
HIV,ortheriskfactorthatSMIitselfmaypose tocontracting
and spreading HIV, the eﬀectiveness of APRN interventions
has not been rigorously studied in this high-risk population.
This paper describes a randomized controlled trial of a
community-based intervention provided by APRNs and
directed at care coordination and at improving adherence
to SMI and HIV treatment regimens. Building sustainable
health networks between the client and a community of
mentalhealth,substanceuse,andprimary careproviderswas
a key objective. Our hypothesis was that, by the 12-month
followup, the patients receiving the home-based APRN
intervention would have experienced greater improvements
in symptoms and quality of life than the control group.
Further, we hypothesized that the outcome response would
be associated with an APRN dose level. Speciﬁcally we
hypothesized that a higher APRN dose would be associated
with a reduction in psychiatric symptoms and improved
health-related quality of life (HRQoL).
3.Materialsand Methods
The study was a longitudinal randomized controlled trial
utilizing a control and intervention group design. The inter-
vention group received advanced practice nurse (APRN)
home-based services over 12 months. The control group
received treatment as usual which may included case man-
agement. Study enrollment began in September 2004 and
ended in April 2008. All study participants provided written,
informed consent. The study was approved by the University
of Pennsylvania Institutional Review Board and by the City
of Philadelphia Health Institutional Review Board.
3.1. Sample. Participants were included in the study if they
(1) were age 18 or older, (2) spoke English, (3) lived within
the city limits of Philadelphia, (4) had a physician diagnosed
SMI, and (5) were HIV positive. They were randomly
assigned to treatment as usual (control group) or to the
intervention group. The sample was recruited by advertise-
ments placed in mental health and HIV treatment facilities.
Participants could self-refer as being HIV positive and
receiving treatment for SMI. Following informed consent,
all participants received a standard HIV screen at baseline
to conﬁrm seropositive status. Any participant not receiving
treatment for HIV was referred to the Infectious Disease
Outpatient Clinic at the Hospital of the University of
Pennsylvania. All participants were paid $40 for each of four
interviews overthe 12-month study period, aswell asfor one
24-monthfollowup.Abonusof$100waspaidtoparticipantsNursing Research and Practice 3
who provided data at all ﬁve study time points. Eligible
consenting participants were randomly assigned on a 1:1
basis to the intervention and control groups. Randomization
ensured that approximately equal numbers of patients were
assigned toeachofthetwogroups,which were balancedwith
respect to observed and unmeasured baseline factors.
Research assistants (RAs) screened and enrolled partic-
ipants after obtaining their informed consent. Once these
processes were completed, the RAs notiﬁed the project man-
ager, who assigned participants to study groups by using
a computer-generated algorithm for randomization. Sub-
sequently, the project director notiﬁed the APRNs when a
participant was assigned to the intervention group. Baseline,
3-, 6-, and 12-month data were collected from both groups
b yt h eR A s ,w h ow e r eb l i n d e dt os t u d yg r o u pa s s i g n m e n t s
and hypotheses. The RAs conducted interviews independent
from the delivery of nursing services.
3.2. Study Intervention. Participants in the intervention
group were assigned an APRN who cared for them over the
52 weeks of the study. The APRNs had a Master’s degree
in nursing; they had a mean of 16.5 years experience in
psychiatric mental health nursing (range 4–30 years). By
protocol, the APRNs were to meet weekly in a face-to-
face contact with the participant. However, phone contact
was the alternative when an appointment could not be
scheduled. At the ﬁrst contact, the APRN obtained a full
health assessment, including gen e r a lm e d i c a l ,m e n t a l ,a n d
environmental health. A plan of care was established in
collaboration with the client with a focus on maximizing the
participant’s ability to self-care. The goal of the program was
to improve client outcomes by clarifying, coordinating, and
managing treatment regimens and addressing individual and
system barriers to care. The APRNsworked closely with each
client’s case manager, boarding homes, shelters, pharmacies,
and clinical providers. APRNs worked toward consistent
and reliable information among the various providers by
attending appointments with the client and, with the client’s
permission, sharing updates in treatment regimens, such
as medication changes and changes in mental and general
health status. APRNs advocated for the client with providers
and coached clients to interact more eﬀectively with their
providers.
3.3.Measures. ChangesinpsychiatricsymptomsandHRQoL
over the 12 months of the intervention were the study
outcomes. HRQoL was measured with the Medical Out-
comes Study 12-Item Short-Form Health Survey (SF-12);
psychiatricsymptomsweremeasured withthePatientHealth
Questionnaire (PHQ-9) and the Colorado Symptom Index
(CSI).
The PHQ-9 is a self-administered screen for depressive
symptoms [22]. The PHQ-9 uses the criteria for depression
from the fourth edition of the Diagnostic and Statistical
Manual for Mental Disorders. Each of the nine items is rated
on a Likert scale from 0 (not at all)t o3( nearly every day).
Scores range from 0 to 27. A score of 10–14 indicates mild
to moderate depression, 15–19 indicates moderately severe
depression, and ≥20 indicates severe depression [22]. The
PHQ-9 is a widely used instrument. In 2006, the Centers for
Disease Control and Prevention and the Center for Mental
Health Services at the Substance Abuse and Mental Health
Services Administration began using the PHQ-9 for state-
level tracking of outcomes. Forty-one states and territories
in 2006 and 16 states in 2008 used the PHQ-9 for outcome
benchmarking [23].
Psychiatric symptoms were assessed with the CSI, the
only psychiatric symptomatology measure developed specif-
ically for community-living persons with mental illnesses.
The CSI is a brief, 14-item self-report scale that measures
psychiatric symptoms an individual has experienced dur-
ing the past month, including anxiety, depression, psy-
chotic symptoms, and disturbed thought process [24, 25].
Responses are made on a 5-point scale that ranges from at
least every day to not at all. The internal consistency of the
instrument is high for the SMI population (α = .89) [24]. A
CSI score >30 indicates moderate to severe illness.
Health-related quality of life (HRQoL) was measured
with the SF-12, which assesses eight health domains: phys-
ical functioning, role-physical, bodily pain, general health,
vitality, social functioning, role activities and mental health.
T h eS F - 1 2i sb a s e do n1 2i t e m st a k e nf r o mt h eS F - 3 6H e a l t h
Survey, a standardized questionnaire used to assess patient
health. The SF-12 is widely used in clinical trials and routine
outcome assessment because of its brevity and psychometric
performance. All SF-12 items are scored so a higher value
indicates a better health state (0–100) [26]. All scores above
or below 50 can be interpreted as above or below the general
population norm. Norm-based scoring algorithms are used
inthisstudyand basedon1998SF-36U.S.populationnorms
[27].
Demographic variables included age, gender, race, mari-
tal status, employment, income, and living situation.
3.4. Nurse Dose. The nurse dose was deﬁned as a combi-
nation of three components: the time, the intensity of the
need (contact, mode, and setting of the communication by
the APRN), and the duration of the APRN intervention.
The nurse dose measure was developed and validated using
an expert panel of nurse researchers. For analysis in this
study, the nurse dose was aggregated to four time points:
baseline to 3 months, 3 months to 6 months, 6 months to
12 months, and baseline to 12 months. Daily logs were kept
by APRNs to collect detailed data on time, service provided,
and communication (contact, mode, and setting).
Time and Type of Service. Time was deﬁned as the time it
took for the APRN to perform a service. The type of service
was deﬁned using the Omaha System (OS) intervention
schema [28]. The OS intervention schema includes four
service types: Teaching Guidanceand Counseling, Treatment
and Procedures, Case Management, and Surveillance. An
APRN could provide all or any of these services in a given
day. Time was assigned to each service then summed for the
day.
Intensity of Need. I tw asdeﬁ n edasac om pos it es c or eofth r ee
categories: (1) contact: the person to whom the intervention4 Nursing Research and Practice
was directed (client, provider, or other), (2) the Mode of
communication (face-to-face, telephone, or other), and (3)
the Setting where the intervention was delivered (home,
oﬃce, or other). Each intensity category was assigned a
discrete number that reﬂected an increasing magnitude of
need (e.g., other=1, provider=3, client=5). The following
assumptions were used to assign an intensity to the three
categories: (a) contact: the client is the most intense focus
of a service; next is a provider, and the least intense are other
persons, (b) mode: face-to-face service is more intense than
telephonecontactandtelephonecontactismoreintensethan
other forms of communication such as e-mail; other is the
least intense form of communication, and (c) setting: the
client’shomeisthemostintenseplacefordeliveringaservice,
theoﬃceissecondandotheristheleastintense.Forexample,
ifthenurse provideda face-to-face interventionforthe client
intheirhome,thetotalintensityofneedscorewouldbeequal
to 15, the highest possible intensity. Intensity of need was
assigned to each service. A composite intensity of need score
was calculated daily.
Duration. The duration of the APRN intervention was
deﬁned as the total number of weeks the client was in
communication with the APRN. As noted above, the study
protocol prescribed 52 weeks of the APRN intervention. The
duration calculation was the actual number of weeks of the
52 weeks that the APRN was in communication with the
participant.
A nurse dose was calculated for each participant in the
intervention group at 3, 6, and 12 months. Steps for calcu-
lating the nurse dose included the following: (1) time and
an intensity score was calculated at the daily level and then
summed for 3, 6, and 12 months and (2) the time and
intensityscoreateachtimepointwasdividedbytheduration
(weeks) to yield the nurse dose for that time period.
For ease of analysis and interpretation, we created a
categorical APRN dose variable for each participant in the
intervention group that reﬂected a low, moderate, or high
dose at each of the four time panels (baseline to 3 months, 3
m o n t h st o6m o n t h s ,6m o n t h st o1 2m o n t h s ,a n db a s e l i n e
to 12 months). This categorization was done by ranking all
continuous dose quantities in the intervention group across
all time periods and then assigning the ﬁrst tertile as 1, the
secondas2,andthetoptertileas3.Participantsinthecontrol
group were assigned a nurse dose of 0.
3.5. Statistical Analysis. Analysis included descriptive mea-
sures and intent-to-treat modelling procedures. Baseline
characteristics were tested for diﬀerences between control
andexperimentalgroupswitht testsfornormally distributed
continuous variables and with Wilcoxon ranked-sum tests
for abnormally distributed variables. Maximum likelihood
chi-square was used for categorical variables. In keeping
with the intent-to-treat principle, participants who did not
complete the study were used in the analyses. Because
of participants’ nonadherence to treatment, the intent-
to-treat analyses likely underestimated the true eﬃcacy
of an intervention. However, the intent-to-treat analyses
accurately estimate eﬀectiveness for any population in which
nonadherence history is similar to that of the intent-to-treat
sample.
W eﬁ r s tr a na na n a l y s i so ft h er e l a t i v ed i ﬀerences in
change between the intervention and control groups for our
measurable outcomes, using a repeated measures random
regression model and the time and group interaction term
in PROC MIXED of SAS 9.2 (SAS Institute, Cary, NC)
to characterize the longitudinal diﬀerences between the
intervention and control arms. We took PHQ-9, CSI, and
SF-12 scores as our outcome measures and derived average
treatment eﬀects (ATEs) for each outcome at each of four
time panels: baseline to 3 months, 3 months to 6 months,
6m o n t h st o1 2m o n t h s ,a n db a s e l i n et o1 2m o n t h s .W e
chose to use a random regression model because it allowed
us to examine the diﬀerences in change in the magnitude of
nurse doseovertime,ortheATE.The implementationofthis
model also permitted us to conduct intent-to-treat analyses
that included participants with missing outcome data at any
time panel under the missing-at-random assumption.
After running our group analysis, we then further
examined the diﬀerences between the control arm and the
three nurse dose subgroups of the intervention arm. Nurse
dose was computed for each intervention participant at the
four time panels and categorized as low dose, moderate
dose, and high dose. We were interested in quantifying the
eﬀect of dose magnitude on changes over time in psychiatric
symptomatology and health-related quality of life at each
time panel. Speciﬁcally, we tested for the eﬀect of dose on
CSI, PHQ-9, and SF-12 scores during each time panel by
using the repeated measures random regression used in the
group analysis. For each of the outcome measures, we used
t h eD o s eL e v e l×Time interaction in the model to calculate
the ATE.
4.Resultsand Discussion
4.1. Demographic and Clinical Characteristics. A total of 238
HIV-positive participants with SMI were enrolled in the
study, of which 128 participants were randomly assigned to
the intervention group and 110 participants were assigned
to the control group. From the intervention group, 3
participants were lost to death and 4 to incarceration; an
additional 4 participants formally withdrew from the study,
and 2 were found ineligible after the randomization process.
From the control group, 5 participants were lost to followup
because of death.
Table 1 shows the patient characteristics of our sample.
The experimental and control groups were similar in all
sociodemographic and baseline health characteristics. Diag-
noses of mental disorders included schizophrenia spectrum
disorders; speciﬁcally, schizophrenia, paranoia, delusional
disorders, psychosis not otherwise speciﬁed, and schizoaf-
fective disorder. Aﬀective disorders were the most common
and included major depression, bipolar disorders, and
anxietydisorders.OtherSMIincludedborderlinepersonality
disorders,substanceuse,acutereactiontostress, andimpulse
disorder.Nursing Research and Practice 5
Table 1: Baseline characteristics of sample receiving an intervention from an advanced practice psychiatric nurse or usual care.
Characteristic
APRN intervention (n = 128) Control (n = 110)
P
n % n %
Age (mean±SD) 43.9±6.6 43.2±7.7 .42
Gender .98
Male 67 52.3 58 52.7
Female 57 44.5 49 44.5
Transgender 4 3.1 3 2.7
Race or ethnicity .47
Black or African American 105 81.9 88 79.1
White 13 10.2 11 10
American Indian 2 1.6 2 1.8
More than one race 0 — 3 2.7
Other 8 6.3 6 6.4
Hispanic or Latino 13 10.2 8 7.3 .58
Education .68
Less than high school 66 51.9 52 47.3
High school 36 27.8 38 34.5
Post-high school technical training 2 1.6 1 0.9
Some college 16 12.3 16 14.5
College degree 5 4 2 1.9
Graduate studies 3 2.4 1 0.9
Current employment status .30
Unemployed 114 89.1 97 88.2
Competitive job 8 6.3 7 6.4
Transitional employment 2 1.6 1 0.9
Work training 2 1.6 0 —
Work in sheltered workshop 1 0.8 0 —
Other 1 0.8 5 4.5
Mental illness .51
Schizophrenia spectrum disorder 25 19.7 28 25.7
Aﬀective disorder 94 73.2 76 68.8
Other serious mental illness 9 7.1 6 5.5
Years from HIV diagnosis to
Baseline interview date (mean±SD) 11.8±5.7 12.4±6.5 .77
4.2. Group-Outcome Analysis. Table 2 shows the ATE esti-
mates between the experimental and control groups for
psychiatric symptoms from the PHQ-9 and CSI. Participants
from both groups experienced decreases in CSI score from
baseline to 12 months, but the relative diﬀerence in these
improvements was not signiﬁcant (d =− 4.03, P = .51
(−15.99,7.83)). During the same period, we found that
PHQ-9 scores in control group decreased (d =− 1.23, P =
.054 (−2.48,0.020)) compared to an overall increase for the
experimental group (d = 3.17, P = .37 (−3.78,10.11]),
resulting in an ATE of an increase in PHQ-9 score of 4.40
(P = .222 (−2.66,11.46)).
With regard to the health-related quality-of-life out-
comes (e.g., SF-12 mental health score), we found that
the Group×Time interactions in our repeated measured
random regression models were all nonsigniﬁcant (P>
.05), suggesting no clear diﬀerence in the changes in these
measurable outcomes over time between the intervention
and control groups. The ATEs for the four time panels did
not show any signiﬁcant trends for any of the quality-of-life
variables. The analysis is available on request.
4.3. Dose-Outcome Analysis. After assigning each interven-
tion participant at each time period a nurse dose level of low,
moderate, or high, we then compared the three dose groups
with the control group. Figure 1 depicts the progression of
the psychiatric symptom outcomes by dose level. The dose-
speciﬁc trends suggest heterogeneity in the eﬀect of the
APRN among experimental participants; that is, outcome
response may have been a function of dose level, rather than
only of treatment group.6 Nursing Research and Practice
Table 2: Average treatment eﬀects for patients receiving an advanced practice psychiatric nurse intervention.
Period Depression (PHQ-9)b Psychiatric symptoms (CSI)c
Eﬀect (d) 95% CI Pa Eﬀect (d) 95% CI Pa
Baseline to 3 months 2.99 −4.01, 9.99 .402 −2.58 −14.35, 9.19 .667
3 months to 6 months 2.39 0.53, 4.24 .012 −0.32 −3.44, 2.79 .841
6m o n t h st o1 2m o n t h s −0.98 −2.97, 1.02 .336 −1.14 −4.46, 2.19 .503
Baseline to 12 months 4.40 −2.66, 11.46 .222 −4.03 −15.99, 7.83 .505
aCompared with participants who received usual care.
bPatientHealth Questionnaire (PHQ-9).
cColorado Symptom Index (CSI).
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Figure 1
Table 3 outlines the regression results for the psychiatric
and depression outcomes. We found that the magnitude and
direction of the reduction of psychiatric symptomatology,
as captured by the CSI score, was most consistent for
participants receiving a high dose of APRN intervention.
High-dose participants showed a reduction in CSI score
at each of the four time panels, and we found that the
reductions in CSI scores for these participants were greater
than the changes in the usual care group at each time point.
In particular, the ATE for the 6- to 12-month period was
−5.63 (P = .05 (−11.2,−0.01)), and −3.69 from baseline to
12 months (P = .102 (−8.1,0.70)). In contrast, participants
receiving a moderate dose had three negative ATEs; from 3
to 6 months, CSI scores of usual care participants decreased
more than for participants receiving a moderate APRN dose
(ATE=0.49, P = .80 (−3.3,4.3)). For participants in the
low-dose category, we found no distinguishable diﬀerences
in reduction of CSI scores, compared with those in the
usual care group. Namely, the CSI scores in the usual
care group decreased more than the CSI scores among the
low-dose participants during two of the four time panels.
Comparisons of reductions in PHQ-9 scores among varying
dose levels followed a trend similar to that of CSI score.
From baseline to 12 months, participants in the high-
dose category experienced an average decrease in PHQ-9
score of 5.314 points (P<. 01 (−7.4,3.16)), compared
with a decrease of 1.148 points for the usual care group
(P = .114 (−2.57,0.27)), for an ATE of −4.17 (P = .002
(−6.7, −1.6)). During the same period with usual care
as the reference group, the ATE was −0.40 (P = .79
(−3.4,2.6)) for moderate-dose participants and −1.07 (P =
.502 (−4.12,2.1)) for those receiving a low dose.
Table 4 summarizes the ATEs for the health-related
quality outcomes. There appeared to be a strong relationship
between APRN dose level and health-related quality-of-life
outcome, as suggested by the signiﬁcant time and nurse dose
interaction terms in the regression models. For example, we
found that participants in the high-dose group improved
their mental health score from baseline to 12 months 0.56
units more than did the usual care group (P = .01),
compared with an ATE for the moderate group of 0.27 units
(P = .27). Further, using general health as our summary
measure, we observed an ATE of 0.55 units from baseline to
12monthsforthehigh-dosegroup(P = .01),comparedwith
−0.02 for the moderate group (P = .95), and −0.19 for the
low-dose group (P = .47).Nursing Research and Practice 7
Table 3: Depression and psychiatric symptom outcomes: average treatment eﬀects for patients receiving an advanced practice psychiatric
nurse intervention, by dose versus usual care.
APRN dose Period Depression (PHQ-9)a Psychiatric symptoms (CSI)b
Eﬀect (d) 95% CI Pc Eﬀect (d) 95% CI Pc
Low
Baseline to 3M −2.35 −5.1, 0.4 .09 −1.50 −5.8, 2.8 .50
3Mto6M 1.81 −0.6, 4.0 .14 0.73 −3.3, 4.8 .73
6Mto12M −0.69 −3.3, 1.9 .60 0.69 −3.5, 4.9 .75
Baseline to 12M −1.07 −4.2, 2.1 .50 −2.11 −7.4, 3.2 .44
Moderate
Baseline to 3M −1.50 −4.2, 1.2 .27 −3.28 −7.6, 1.0 .14
3Mto6M 2.39 0.2, 4.6 .03 0.49 −3.3, 4.3 .80
6Mto12M −1.90 −4.9, 1.1 .22 −2.23 −7.1, 2.6 .37
Baseline to 12M −0.40 −3.4, 2.6 .79 −4.40 −9.4, 0.6 .09
High
Baseline to 3M −4.19 −6.4, –2.0 <.001 −0.74 −4.2, 2.7 .68
3Mto6M 2.26 −0.9, 5.4 .16 −3.11 −8.5, 2.3 .26
6Mto12M −1.60 −5.1, 1.9 .36 −5.63 −11.2, −0.01 .05
Baseline to 12M −4.17 −6.7, –1.6 .00 −3.69 −8.1, 0.7 .10
Note. Negative eﬀect values indicate a decrease in symptomsand improvement.
aPatienthealth questionnaire (Colorado symptom Index).
bColorado symptom Index.
cCompared with participants who received usual care.
5.Discussion
This study of the eﬀectiveness of a care management
intervention by APRNs for patients with SMI and HIV
demonstrated improvement in symptoms and health-related
quality of life. The ATE showed signiﬁcant reductions in
symptoms for the intervention group at the higher nurse
dose level but not at the low or moderate nurse dose level.
These results suggest that care management by APRNs may
be a useful strategy for improving care and outcomes for
high need individuals with SMI and HIV. The APRNs facil-
itated improvement through a combination of education,
medication management, and advocacy within the health
system. These ﬁndings are consistent with a growing body
of literature that suggests that care management models
are beneﬁcial for vulnerable populations. People with SMI
and HIV share with these populations high risk for adverse
outcomes due to complex medical and psychiatric proﬁles
and complicated treatment regimens.
Components of the APRN care management interven-
tion make it an appealing approach for improving treat-
ment outcomes among community-dwelling individuals
withSMI.APRNshavethespecialtyeducationthatintegrates
mental and general health care. The system-level barriers
are often insurmountable for individuals with SMI. Care is
delayed or not obtained at all, and the illness continues to
worsen, often developing into a full-blown crisis needing
high-end and expensive care in emergency departments or
hospitalization. Compared with usual care, care manage-
ment by APRNs may be a more eﬃcient approach for the
high-risk SMI and HIV population. The APRN provides
patient-centered care by delivering services in the client’s
home environment. Additionally, the client has quick access
toadvanced assessment andsurveillanceofanAPRN.Studies
using APRNs versus registered nurses show the APRN to be
more eﬀective in meeting the needs of high-risk populations
because they have the authority to manage the health care
needs in the moment without the delay of referral to a
physician [29]. APRNs are independently licensed in most
states to prescribe and treat health conditions. Improving
accessibility to health care might be associated with mental
health improvement over the long term by lowering stress
level. Future studies need to evaluate health biomarkers such
as cardiometabolic markers over the long term to establish
overall improvement in health in this population [30].
In both the intervention and control groups, participants
h a dh i g hP H Q - 9a n dC S Is c o r e si n d i c a t i n gam o d e r a t et o
high level of psychiatric symptoms when compared with
the general public. In addition, the participants scored
consistentlylower onthehealth-related quality-of-lifesurvey
than the general population. Many other studies have shown
similar refractory patterns in symptoms with the SMI
population [30]. Changes or improvement in conditions are
diﬃcult to detect. In our study, the APRN dose-response
analysis showed patterns not revealed in standard group
analyses. For example, heterogeneity in the eﬀect of the
APRN intervention was discovered among the intervention
participants, indicating that the outcome response may be
a function of dose level, rather than only treatment group.
From another point of view, the dose-eﬀect pattern shows
there are individuals who may require higher doses of the
APRN to achieve improvement.
Figure 1 demonstrates patterns of response to the APRN
dose. Compared with the control group, it appears that the
intervention group who had low and moderate APRN dose
had lower depression scores (PHQ-9) in all 12 months of
the study. The high APRN dose receivers showed a diﬀerent
pattern. Depression appeared to improve in the ﬁrst 3
months thenworsened in the 3 to 6 month time period, then
improved again in the last 6 months of the study. Figure 18 Nursing Research and Practice
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also shows patterns in psychiatric symptoms (CSI). All levels
of the APRN dose recipients show greater improvement
than the controls. Most important is the observation that
there are diﬀerent patterns among those in the intervention
group. High-dose participants experienced a reduction in
CSI score of 3–5 points at each of the four time panels, and
we found that the reductions in the CSI score were greater
for participants in the intervention group than for those in
the usual care group at each time point. Other than noting
the direction of the change and diﬀerences among the dose
recipients and the control group, we are reluctant to draw
conclusions. Future studies are required to benchmark the
response to APRN interventions.
As health care reform is implemented, an opportunity
presents itself to ensure that system changes are made in the
provision of care for complex patient populations, such as
those with HIV and SMI. In the current health care system,
the SMI patient with HIV infection would most likely be
referred to an HIV medical provider in a location separate
from his or her mental health care, requiring the patient to
be responsible for arranging and keeping the appointment
as well as ﬁnding transportation. This fragmented system
does not promote optimal outcomes for the HIV-SMI
population.The conceptofthe “health home” that promotes
collaborative care among specialties could be translated
into APRN-led treatment centers in the community that
provide cost-eﬀective and quality care speciﬁcally to this
population. In this sense, the “home” for receiving health
care services (physical and mental health) could be a virtual
home centered on a home care model.
We note some limitations to our study. The APRNs
used in this study were university based and had training in
research. Therefore, results may or may not be diﬀerent from
community-based nurses. Although the control group was
notgiventhenursing intervention,therepeatedinterviewing
bytheresearch assistants atthemultipletimepointscouldbe
considered a form of “intervention.” The idea is supported
by the fact that the control group experienced improve-
ments similar to the intervention group. The addition of a
third APRN without the intended reduction of randomized
assignments to the ﬁrst two nurses resulted in unequal
randomization probabilities and an imbalance in sample
sizes across treatment groups and the three nurses. A fourth
nurse was used as a replacement for the ﬁrst two nurses for
a subset of patients. These changes may have inserted an
indirect bias into the study.
6.Conclusions
This study demonstrated that people with SMI and HIV
could achieve improvement with APRN care management
services. This population is a high need, high cost subgroup
with poor quality of overall health. The personal and societal
costs of these problems are staggering. Implementation
of community-based nurse management using APRNs for
complex patient populations may improve long-term out-
comes and reduce the high costs of care. This study suggests
that APRN care management should be a central component
of the redesign of health care delivery to this vulnerable
population.
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